News

Press Releases

10/25/2024

The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics

10/16/2023

The Retinal Degeneration Fund Announces an Investment in NVasc

08/24/2023

The Retinal Degeneration Fund announces an investment in Amber Bio

02/28/2023

RD Fund Appoints Mark S. Blumenkranz, MD, MMS to Board of Directors

01/06/2023

The Retinal Degeneration Fund invests in a $78M Series B for Perceive Biotherapeutics

11/10/2022

Foundation Launching its Largest Natural History Study to Date for 1,500 People with Inherited Retinal Diseases Caused by Rare Mutated Genes

09/15/2022

RD Fund Participates in a €75 Million Series B for SparingVision

07/21/2022

RD Fund Announces New Chair, and Expansion of Board of Directors

06/21/2022

Foundation Fighting Blindness Announces Leadership Changes

06/15/2022

Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing Led by Foundation Fighting Blindness & RD Fund

03/08/2022

Foundation Fighting Blindness and InformedDNA Partner to Engage and Screen Patients for ProQR’s Pivotal Usher Syndrome and Retinitis Pigmentosa Clinical Trials

01/19/2022

Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officer

01/06/2022

RD Fund Announces Series B Financing Behind SalioGen Therapeutics

10/28/2021

RD Fund Announces Fundraising Efforts Underway for RD Fund 2

10/04/2021

RD Fund Appoints Tony Adamis, MD to Board of Directors

09/22/2021

RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions

10/23/2018

Foundation Fighting Blindness Launches Retinal Degeneration Fund With More Than $70 million of Initial Funding

02/12/2018

Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A

01/18/2018

Foundation Fighting Blindness Supporting Clinical Development of NACA, Promising New Drug for Many Forms of RP

Load More

Articles

10/24/2024

SparingVision Presents Updates on PRODYGY Trial and PHENOROD2 Study at ESGCT 2024

10/22/2024

Ocuphire Pharma Announces Acquisition of Opus Genetics

09/23/2024

SparingVision Reports Progress on SPVN06 at Major Ophthalmology Conferences

09/05/2024

Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet

08/20/2024

Opus Genetics Receives Rare Pediatric Disease Designation from the U.S. FDA for Ocular Gene Therapy OPGx-LCA5 to Treat Rare Inherited Retinal Disease LCA5

08/14/2024

Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis

06/18/2024

Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases

06/13/2024

Opus Genetics Announces $1.7 Million in Project-based Funding from the Foundation Fighting Blindness to Support Two Preclinical Programs

05/13/2024

SparingVision Presents One Year Results from the PHENOROD2 Natural History Study and Preliminary SPVN06 Safety Data at Key Congresses

05/01/2024

Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)

04/30/2024

Nacuity Pharmaceuticals Announces First Patients Implanted in Final Cohort of Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression

04/17/2024

SalioGen Therapeutics Announces Selection Of Development Candidate For ABCA4-Mediated Stargardt Disease

04/16/2024

Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.

03/26/2024

Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5

02/15/2024

Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease Advocate Daniel Feller

02/08/2024

SparingVision Presents Initial SPVN06 Safety Data at the Macula Society 47th Annual Meeting

12/08/2023

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

12/04/2023

Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)

11/14/2023

Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)

11/03/2023

New Preliminary Clinical Data on Potential of Opus AAV-based Gene Therapy for Rare Inherited Retinal Disease to be Presented at the American Academy of Ophthalmology Annual Conference 2023

09/26/2023

SparingVision Selects Second Target in Strategic Collaboration with Intellia Therapeutics

09/07/2023

Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5

08/30/2023

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial

08/03/2023

Amber Bio Raises $26 Million Seed Financing Co-Led by Playground Global and Andreessen Horowitz to Advance New RNA-Based Gene Editing Platform

08/01/2023

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets

07/11/2023

Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression

06/09/2023

The Retinal Research Community Mourns the Loss of Retinal Research Pioneer Thierry Léveillard

05/31/2023

Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome

05/22/2023

SparingVision Presents New Data on SPVN20 Program at ASGCT 2023

05/01/2023

Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis

04/27/2023

SparingVision Presents Progress of its Lead Gene Therapy Program SPVN06 at ARVO 2023

04/25/2023

Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)

12/28/2022

Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases

12/01/2022

SparingVision's lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa

12/01/2022

Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5

11/08/2022

Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Russell Kelley

11/08/2022

Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer

10/12/2022

Ascidian Therapeutics Launches to Rewrite RNA

10/03/2022

Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)

09/27/2022

Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves

08/12/2022

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

07/27/2022

Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle

07/21/2022

Opus Genetics Expands its Leadership Team

07/11/2022

Opus Genetics to Present at OIS Retina Innovation Summit 2022

05/11/2022

Opus Genetics Appoints Jennifer Hunt Chief Development Officer

02/15/2022

Opus Genetics Appoints Brian Leising Vice President, Manufacturing

02/11/2022

ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

01/05/2022

SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene Coding™ – A New Category of Genetic Medicine

12/16/2021

ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

12/09/2021

SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer

12/06/2021

Gyroscope Therapeutics Announces Appointment of Tony Adamis to Board of Directors

12/02/2021

Startup spotlight: Opus Genetics, with $19M, works to advance cures for blinding retinal diseases

11/30/2021

Opus Genetics announces licensing of third program for inherited retinal disease

11/11/2021

Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease

11/08/2021

Opus Genetics Announces Presence at Eyecelerator@AAO 2021

10/28/2021

Pfizer, Novartis sign on to accelerate gene therapies for rare diseases with US agencies

10/20/2021

Opus Genetics Announces Two Key Leadership Appointments

10/13/2021

Intellia beefs up ocular pipeline with 10% stake in SparingVision

10/13/2021

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

10/04/2021

ProQR Appoints Theresa Heggie as Chief Commercial Officer

09/22/2021

Luxturna inventor Jean Bennett starts a new gene therapy company to tackle rare diseases left behind by pharma, VCs

07/29/2021

To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing

07/12/2021

Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors

06/04/2021

Venture philanthropy: The secret weapon for unlocking biomedical research's full life-changing potential

05/18/2021

Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies

03/24/2021

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials

03/19/2021

SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

02/04/2021

Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision

01/29/2021

Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board

12/16/2020

Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases

11/09/2020

Stargazer Pharmaceuticals, Inc. Announces $57 Million Series A Financing and Initiation of a Phase 2a Clinical Study of STG-001 in Stargardt Disease Patients

10/29/2020

Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company

10/21/2020

SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer

07/29/2020

Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis

05/18/2020

Nacuity Pharmaceuticals Announces Initiation of SLO-RP (Safety and Efficacy of NPI-001 Tablets versus PLacebO for Treatment of Retinitis Pigmentosa Associated with Usher Syndrome) Phase 1/2 Clinical Trial

04/28/2020

CheckedUp Launches Virtual Visits, Advanced Telehealth Platform for Specialty Care

03/31/2020

ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update

07/09/2019

SparingVision Awarded at EIC Accelerator Program (H2020 SME Instrument Phase 2), Securing Funding of €2.5 Million

03/11/2019

ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

07/12/2017

SparingVision Formed to Advance Sight-Saving Protein for RP

Load More